메뉴 건너뛰기




Volumn 98, Issue 12, 2013, Pages 1930-1938

Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells

Author keywords

[No Author keywords available]

Indexed keywords

AMG 103; BLINATUMOMAB; CD28 ANTIGEN; CD3 ANTIBODY; CD38 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 8; KI 67 ANTIGEN; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

EID: 84889849596     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.082248     Document Type: Article
Times cited : (69)

References (50)
  • 1
    • 2942584865 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia: Revelations from the B-cell receptor
    • Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103(10):4389-95.
    • (2004) Blood , vol.103 , Issue.10 , pp. 4389-4395
    • Stevenson, F.K.1    Caligaris-Cappio, F.2
  • 3
    • 77949446259 scopus 로고    scopus 로고
    • Allotransplantation for chronic lymphocytic leukemia
    • Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2009:602-9.
    • (2009) Hematology Am Soc Hematol Educ Program , pp. 602-609
    • Dreger, P.1
  • 5
    • 0038811776 scopus 로고    scopus 로고
    • Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network
    • Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21(9):1746-51.
    • (2003) J Clin Oncol , vol.21 , Issue.9 , pp. 1746-1751
    • Hainsworth, J.D.1    Litchy, S.2    Barton, J.H.3    Houston, G.A.4    Hermann, R.C.5    Bradof, J.E.6
  • 6
    • 77957664665 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial
    • Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
    • (2010) Lancet , vol.376 , Issue.9747 , pp. 1164-1174
    • Hallek, M.1    Fischer, K.2    Fingerle-Rowson, G.3    Fink, A.M.4    Busch, R.5    Mayer, J.6
  • 7
    • 77950478885 scopus 로고    scopus 로고
    • Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia
    • Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010; 28(10):1756-65.
    • (2010) J Clin Oncol , vol.28 , Issue.10 , pp. 1756-1765
    • Robak, T.1    Dmoszynska, A.2    Solal-Celigny, P.3    Warzocha, K.4    Loscertales, J.5    Catalano, J.6
  • 8
    • 11144357657 scopus 로고    scopus 로고
    • Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
    • Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103(9):3278-81.
    • (2004) Blood , vol.103 , Issue.9 , pp. 3278-3281
    • Lozanski, G.1    Heerema, N.A.2    Flinn, I.W.3    Smith, L.4    Harbison, J.5    Webb, J.6
  • 9
    • 27244451794 scopus 로고    scopus 로고
    • Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial
    • Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005;23(28):7024-31.
    • (2005) J Clin Oncol , vol.23 , Issue.28 , pp. 7024-7031
    • Elter, T.1    Borchmann, P.2    Schulz, H.3    Reiser, M.4    Trelle, S.5    Schnell, R.6
  • 10
    • 33749452185 scopus 로고    scopus 로고
    • Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia
    • Winkler D, Dohner H, Stilgenbauer S. Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia. Curr Drug Targets. 2006;7(10):1313-27.
    • (2006) Curr Drug Targets , vol.7 , Issue.10 , pp. 1313-1327
    • Winkler, D.1    Dohner, H.2    Stilgenbauer, S.3
  • 11
    • 67449156132 scopus 로고    scopus 로고
    • Bispecific T-cell engaging antibodies for cancer therapy
    • Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(19509221):4941-4.
    • (2009) Cancer Res , vol.69 , pp. 4941-4944
    • Baeuerle, P.A.1    Reinhardt, C.2
  • 12
    • 79959312575 scopus 로고    scopus 로고
    • Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
    • Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-8.
    • (2011) J Clin Oncol , vol.29 , Issue.18 , pp. 2493-2498
    • Topp, M.S.1    Kufer, P.2    Gokbuget, N.3    Goebeler, M.4    Klinger, M.5    Neumann, S.6
  • 13
    • 49649120397 scopus 로고    scopus 로고
    • Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
    • Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321 (5891):974-7.
    • (2008) Science , vol.321 , Issue.5891 , pp. 974-977
    • Bargou, R.1    Leo, E.2    Zugmaier, G.3    Klinger, M.4    Goebeler, M.5    Knop, S.6
  • 14
    • 84867857964 scopus 로고    scopus 로고
    • Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. American Society of Hematology meeting 2011
    • Viardot A, Goebeler, M, Noppeney R, Krause SW, Kallert S, Ferstl B, et al. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. American Society of Hematology meeting 2011, Abstract 1637; 2011.
    • (2011) Abstract , pp. 1637
    • Viardot, A.1    Goebeler, M.2    Noppeney, R.3    Krause, S.W.4    Kallert, S.5    Ferstl, B.6
  • 15
    • 0034782326 scopus 로고    scopus 로고
    • Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL)
    • Porakishvili N, Roschupkina T, Kalber T, Jewell AP, Patterson K, Yong K, et al. Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol. 2001;126(1):29-36.
    • (2001) Clin Exp Immunol , vol.126 , Issue.1 , pp. 29-36
    • Porakishvili, N.1    Roschupkina, T.2    Kalber, T.3    Jewell, A.P.4    Patterson, K.5    Yong, K.6
  • 16
    • 46749132717 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
    • Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-37.
    • (2008) J Clin Invest , vol.118 , Issue.7 , pp. 2427-2437
    • Ramsay, A.G.1    Johnson, A.J.2    Lee, A.M.3    Gorgün, G.4    Le Dieu, R.5    Blum, W.6
  • 17
    • 79953814653 scopus 로고    scopus 로고
    • Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL
    • Christopoulos P, Pfeifer D, Bartholomé K, Follo M, Timmer J, Fisch P, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood. 2011;117(14):3836-46.
    • (2011) Blood , vol.117 , Issue.14 , pp. 3836-3846
    • Christopoulos, P.1    Pfeifer, D.2    Bartholomé, K.3    Follo, M.4    Timmer, J.5    Fisch, P.6
  • 18
    • 0032851693 scopus 로고    scopus 로고
    • Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia
    • Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;106(4):995-1004.
    • (1999) Br J Haematol , vol.106 , Issue.4 , pp. 995-1004
    • Kitada, S.1    Zapata, J.M.2    Andreeff, M.3    Reed, J.C.4
  • 19
    • 4344664011 scopus 로고    scopus 로고
    • A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells
    • Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004;18(8):1391-00.
    • (2004) Leukemia , vol.18 , Issue.8 , pp. 1391-1400
    • Cuni, S.1    Perez-Aciego, P.2    Perez-Chacon, G.3    Vargas, J.A.4    Sanchez, A.5    Martin-Saavedra, F.M.6
  • 20
    • 66149147044 scopus 로고    scopus 로고
    • Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
    • Vogler M, Butterworth M, Majid A, Walewska RJ, Sun X-M, Dyer MJS, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113(18):4403-13.
    • (2009) Blood , vol.113 , Issue.18 , pp. 4403-4413
    • Vogler, M.1    Butterworth, M.2    Majid, A.3    Walewska, R.J.4    Sun, X.-M.5    Dyer, M.J.S.6
  • 21
    • 84865108469 scopus 로고    scopus 로고
    • Mimicking the tumour microenvironment: Three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells
    • Hamilton E, Pearce L, Morgan L, Robinson S, Ware V, Brennan P, et al. Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Br J Haematol. 2012;158(5):589-99.
    • (2012) Br J Haematol , vol.158 , Issue.5 , pp. 589-599
    • Hamilton, E.1    Pearce, L.2    Morgan, L.3    Robinson, S.4    Ware, V.5    Brennan, P.6
  • 22
    • 24744432528 scopus 로고    scopus 로고
    • Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
    • Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018-25.
    • (2005) Blood , vol.106 , Issue.6 , pp. 2018-2025
    • Beyer, M.1    Kochanek, M.2    Darabi, K.3    Popov, A.4    Jensen, M.5    Endl, E.6
  • 23
  • 24
    • 79952100710 scopus 로고    scopus 로고
    • Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease
    • D'Arena G, Laurenti L, Minervini MM, Deaglio S, Bonello L, De Martino L, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res. 2011;35(3):363-8.
    • (2011) Leuk Res , vol.35 , Issue.3 , pp. 363-368
    • D'Arena, G.1    Laurenti, L.2    Minervini, M.M.3    Deaglio, S.4    Bonello, L.5    de Martino, L.6
  • 25
    • 84856515333 scopus 로고    scopus 로고
    • Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression
    • Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res. 2012;18(3): 678-87.
    • (2012) Clin Cancer Res , vol.18 , Issue.3 , pp. 678-687
    • Nunes, C.1    Wong, R.2    Mason, M.3    Fegan, C.4    Man, S.5    Pepper, C.6
  • 26
    • 32644448488 scopus 로고    scopus 로고
    • A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation
    • Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006;107(4):1325-31.
    • (2006) Blood , vol.107 , Issue.4 , pp. 1325-1331
    • Porter, D.L.1    Levine, B.L.2    Bunin, N.3    Stadtmauer, E.A.4    Luger, S.M.5    Goldstein, S.6
  • 27
    • 26944462424 scopus 로고    scopus 로고
    • Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia
    • Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia. 2005;19(9): 1621-7.
    • (2005) Leukemia , vol.19 , Issue.9 , pp. 1621-1627
    • Hus, I.1    Roliński, J.2    Tabarkiewicz, J.3    Wojas, K.4    Bojarska-Junak, A.5    Greiner, J.6
  • 28
    • 80051720194 scopus 로고    scopus 로고
    • Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
    • Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-33.
    • (2011) N Engl J Med , vol.365 , Issue.8 , pp. 725-733
    • Porter, D.L.1    Levine, B.L.2    Kalos, M.3    Bagg, A.4    June, C.H.5
  • 29
    • 51349123970 scopus 로고    scopus 로고
    • Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia
    • Foster AE, Brenner MK, Dotti G. Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2008;21(3):375-89.
    • (2008) Best Pract Res Clin Haematol , vol.21 , Issue.3 , pp. 375-389
    • Foster, A.E.1    Brenner, M.K.2    Dotti, G.3
  • 30
    • 0025345496 scopus 로고
    • Individual variation in the frequency of HLA class II-specific cytotoxic T lymphocyte precursors
    • Man S, Lechler RI, Batchelor JR, Sharrock CE. Individual variation in the frequency of HLA class II-specific cytotoxic T lymphocyte precursors. Eur J Immunol. 1990;20 (4):847-54.
    • (1990) Eur J Immunol , vol.20 , Issue.4 , pp. 847-854
    • Man, S.1    Lechler, R.I.2    Batchelor, J.R.3    Sharrock, C.E.4
  • 31
    • 72649087324 scopus 로고    scopus 로고
    • Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4 perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotype
    • Walton JA, Lydyard PM, Nathwani A, Emery V, Akbar A, Glennie MJ, et al. Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4 perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotype. Br J Haematol. 2010;148(2):274-84.
    • (2010) Br J Haematol , vol.148 , Issue.2 , pp. 274-284
    • Walton, J.A.1    Lydyard, P.M.2    Nathwani, A.3    Emery, V.4    Akbar, A.5    Glennie, M.J.6
  • 32
    • 0037851832 scopus 로고    scopus 로고
    • Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific antiCD19/anti-CD3 single-chain antibody construct
    • Löffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific antiCD19/anti-CD3 single-chain antibody construct. Leukemia. 2003;17(5):900-9.
    • (2003) Leukemia , vol.17 , Issue.5 , pp. 900-909
    • Löffler, A.1    Gruen, M.2    Wuchter, C.3    Schriever, F.4    Kufer, P.5    Dreier, T.6
  • 33
    • 58549109813 scopus 로고    scopus 로고
    • Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
    • d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res. 2009;33(3):465-73.
    • (2009) Leuk Res , vol.33 , Issue.3 , pp. 465-473
    • D'Argouges, S.1    Wissing, S.2    Brandl, C.3    Prang, N.4    Lutterbuese, R.5    Kozhich, A.6
  • 34
    • 18944364610 scopus 로고    scopus 로고
    • Effect of CD3/CD28 bead-activated and expanded T cells on leukemic B cells in chronic lymphocytic leukemia
    • Patten P, Devereux S, Buggins A, Bonyhadi M, Frohlich M, Berenson RJ. Effect of CD3/CD28 bead-activated and expanded T cells on leukemic B cells in chronic lymphocytic leukemia. J Immunol. 2005;174(11): 6562-3.
    • (2005) J Immunol , vol.174 , Issue.11 , pp. 6562-6563
    • Patten, P.1    Devereux, S.2    Buggins, A.3    Bonyhadi, M.4    Frohlich, M.5    Berenson, R.J.6
  • 35
  • 36
    • 0028356439 scopus 로고
    • Cytokine gene expression in B-cell chronic lymphocytic leukemia: Evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein
    • di Celle PF, Carbone A, Marchis D, Zhou D, Sozzani S, Zupo S, et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood. 1994;84(1):220-8.
    • (1994) Blood , vol.84 , Issue.1 , pp. 220-228
    • di Celle, P.F.1    Carbone, A.2    Marchis, D.3    Zhou, D.4    Sozzani, S.5    Zupo, S.6
  • 37
    • 0036090816 scopus 로고    scopus 로고
    • Intracellular tumor necrosis factor production by T-and B-cells in B-cell chronic lymphocytic leukemia
    • Bojarska-Junak A, Rolinski J, Wasik-Szczepaneko E, Kaluzny Z, Dmoszynska A. Intracellular tumor necrosis factor production by T-and B-cells in B-cell chronic lymphocytic leukemia. Haematologica. 2002;87 (5):490-9.
    • (2002) Haematologica , vol.87 , Issue.5 , pp. 490-499
    • Bojarska-Junak, A.1    Rolinski, J.2    Wasik-Szczepaneko, E.3    Kaluzny, Z.4    Dmoszynska, A.5
  • 38
    • 28944434529 scopus 로고    scopus 로고
    • Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
    • Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006;43(6): 763-71.
    • (2006) Mol Immunol , vol.43 , Issue.6 , pp. 763-771
    • Offner, S.1    Hofmeister, R.2    Romaniuk, A.3    Kufer, P.4    Baeuerle, P.A.5
  • 39
    • 11444259307 scopus 로고    scopus 로고
    • Microenvironmental interactions and survival of CLL B-cells
    • Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma. 2004;45(12):2365-72.
    • (2004) Leuk Lymphoma , vol.45 , Issue.12 , pp. 2365-2372
    • Munk, P.I.1    Reed, J.2
  • 40
    • 77957367164 scopus 로고    scopus 로고
    • The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia CXCR4 antagonists as potential adjuvants for monoclonal antibodies
    • Buchner M, Brantner P, Stickel N, Prinz G, Burger M, Bar C, et al. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol. 2010;151(2):167-78.
    • (2010) Br J Haematol , vol.151 , Issue.2 , pp. 167-178
    • Buchner, M.1    Brantner, P.2    Stickel, N.3    Prinz, G.4    Burger, M.5    Bar, C.6
  • 41
    • 0034667624 scopus 로고    scopus 로고
    • Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1
    • Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-63.
    • (2000) Blood , vol.96 , Issue.8 , pp. 2655-2663
    • Burger, J.A.1    Tsukada, N.2    Burger, M.3    Zvaifler, N.J.4    Dell'Aquila, M.5    Kipps, T.J.6
  • 42
    • 70549101249 scopus 로고    scopus 로고
    • Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles
    • Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Ivanyi J, Schmitz G, et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia. 2009;23(11):2118-28.
    • (2009) Leukemia , vol.23 , Issue.11 , pp. 2118-2128
    • Plander, M.1    Seegers, S.2    Ugocsai, P.3    Diermeier-Daucher, S.4    Ivanyi, J.5    Schmitz, G.6
  • 43
    • 0027499535 scopus 로고
    • Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal
    • Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177(4):925-35.
    • (1993) J Exp Med , vol.177 , Issue.4 , pp. 925-935
    • Ranheim, E.A.1    Kipps, T.J.2
  • 44
    • 0030971074 scopus 로고    scopus 로고
    • Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies
    • Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol. 1997;97(2):409-17.
    • (1997) Br J Haematol , vol.97 , Issue.2 , pp. 409-417
    • Wang, D.1    Freeman, G.J.2    Levine, H.3    Ritz, J.4    Robertson, M.J.5
  • 45
    • 0032147205 scopus 로고    scopus 로고
    • Triggering of CD40 antigen inhibits fludarabineinduced apoptosis in B chronic lymphocytic leukemia cells
    • Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, et al. Triggering of CD40 antigen inhibits fludarabineinduced apoptosis in B chronic lymphocytic leukemia cells. Blood. 1998;92(3):990-5.
    • (1998) Blood , vol.92 , Issue.3 , pp. 990-995
    • Romano, M.F.1    Lamberti, A.2    Tassone, P.3    Alfinito, F.4    Costantini, S.5    Chiurazzi, F.6
  • 47
    • 81055149605 scopus 로고    scopus 로고
    • CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
    • Jak M, van Bochove GGW, Reits EA, Kallemeijn WW, Tromp JM, Umana P, et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood. 2011;118 (19):5178-88.
    • (2011) Blood , vol.118 , Issue.19 , pp. 5178-5188
    • Jak, M.1    van Bochove, G.G.W.2    Reits, E.A.3    Kallemeijn, W.W.4    Tromp, J.M.5    Umana, P.6
  • 48
    • 17644385543 scopus 로고    scopus 로고
    • Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
    • Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115(1):98-104.
    • (2005) Int J Cancer , vol.115 , Issue.1 , pp. 98-104
    • Hoffmann, P.1    Hofmeister, R.2    Brischwein, K.3    Brandl, C.4    Crommer, S.5    Bargou, R.6
  • 49
    • 51349099954 scopus 로고    scopus 로고
    • Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands
    • Mous R, Savage P, Eldering E, Teeling P, van Oers MH, van Lier RA. Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands. Leuk Lymphoma. 2008;49(8):1592-602.
    • (2008) Leuk Lymphoma , vol.49 , Issue.8 , pp. 1592-1602
    • Mous, R.1    Savage, P.2    Eldering, E.3    Teeling, P.4    van Oers, M.H.5    van Lier, R.A.6
  • 50
    • 84863522243 scopus 로고    scopus 로고
    • Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
    • Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26): 6226-33.
    • (2012) Blood , vol.119 , Issue.26 , pp. 6226-6233
    • Klinger, M.1    Brandl, C.2    Zugmaier, G.3    Hijazi, Y.4    Bargou, R.C.5    Topp, M.S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.